Welcome to Awesome Blog Design perfect blog
Business, Healthcare, Local News

U.S. Food and Drug Administration approves OPDIVO® (nivolumab) in combination with CABOMETYX® (cabozantinib) as first-line treatment for patients with advanced renal cell carcinoma

In CheckMate -9ER, OPDIVO in combination with CABOMETYX doubled median progression-free survival and objective response rate and showed superior overall survival vs. sunitinib1 Approved across all International Metastatic Renal Cell Carcinoma Database Consortium risk categories1,2 Approval expands Company’s presence in first-line advanced

Business, Healthcare, Local News

U.S. Food and Drug Administration accepts for Priority Review Application for Opdivo® (nivolumab) combined with chemotherapy as first-line treatment in metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma

U.S. Food and Drug Administration assigned a target action date of May 25, 2021 PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License

Business, Healthcare, Local News

European Medicines Agency validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as adjuvant treatment for resected esophageal or gastroesophageal junction cancer following chemoradiotherapy

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for esophageal or gastroesophageal junction (GEJ) cancer in adult patients